Welcome to our dedicated page for PetMed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on PetMed Express stock.
PetMed Express, Inc. (NASDAQ: PETS), widely recognized as PetMeds, is America's largest pet pharmacy. Established in 1996, PetMeds provides both prescription and non-prescription pet medications, health products, and nutritional supplements for dogs, cats, and horses directly to consumers at substantial savings. The company operates from a single location, delivering exceptional value and convenience to millions of satisfied customers nationwide.
PetMeds generates revenue primarily by selling pet medications and supplies, targeting retail consumers. The company prides itself on being a trusted pet health expert, offering competitive prices and convenient access to a wide range of products. Pet parents can purchase these products through PetMeds' toll-free number (1-800-PetMeds) or online at www.petmeds.com.
Recently, PetMeds partnered with Hill's Pet Nutrition to offer Hill's Science Diet products on PetMeds' platform starting March 1, 2024. To celebrate this partnership, PetMeds launched a promotional giveaway, providing a year's worth of Hill's Science Diet to one lucky winner. This initiative aligns with PetMeds' commitment to responsible pet ownership and support for animal shelters facing capacity crises.
PetMeds also offers innovative services like Pumpkin® pet insurance plans and same-day VetLive® telehealth appointments, making veterinary care more accessible and affordable. Furthermore, through its wholly-owned subsidiary, PetCareRx, PetMeds extends its reach by providing additional pet health products and services.
The company's financial stability is underscored by its consistent performance and strategic partnerships. PetMeds is scheduled to host a conference call on February 8, 2024, to discuss its third-quarter results, followed by a Q&A session. This event provides an opportunity for investors and stakeholders to gain insights into the company's operations and future plans.
For more information, visit www.petmeds.com or contact PetMeds' investor relations team at investor@petmeds.com.
PetMed Express announced its Q3 2021 financial results, reporting net sales of $60.7 million, a 7.9% decrease from the previous year. For the nine months, net sales were $207.4 million, down 12.7%. The net income for the quarter declined 44% to $4.3 million, equating to $0.21 diluted per share. Adjusted EBITDA also fell 31% to $7.6 million. Despite these declines, the average order size increased slightly from $88 to $89. The Board declared a quarterly dividend of $0.30 per share, payable on February 18, 2022.
PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for Q3 2021 on January 24, 2022, at 4:00 PM ET, followed by a conference call at 4:30 PM ET. The call is accessible to the public through a toll-free number and will also be available via webcast. For those who cannot attend live, a replay will be available from 7:30 PM ET on January 24 until February 7, 2022. Founded in 1996, PetMed Express provides prescription and non-prescription pet medications and health products directly to consumers.
PetMed Express, Inc. announced the hiring of three executives to drive its digital transformation and growth. Mark Moseley joins as Chief Technology and Information Officer, bringing 17 years of experience from Rosetta Stone. Dan Pingree is the new Chief Marketing Officer, known for his role in selling Moosejaw to Walmart, along with experience at Drugstore.com. Jacqueline Smith takes the role of Vice President of People, previously leading HR at Anju Software. CEO Matt Hulett emphasizes these hires are crucial for enhancing the company's e-commerce capabilities.
PetMed Express (NASDAQ: PETS) reported a 10.7% decrease in net sales for Q2 2021, totaling $67.4 million compared to $75.4 million in Q2 2020. For the first half, sales dropped 14.5% to $146.7 million. Net income fell 24.5% to $6.3 million or $0.31 per share, down from $8.4 million or $0.42 per share year-over-year. The company launched the “AutoShip and Save” program to enhance customer retention. A quarterly dividend of $0.30 per share has been declared, payable on November 19, 2021.
PetMed Express, Inc. (NASDAQ: PETS) will release its financial results for the quarter ending September 30, 2021, on October 25, 2021, at 4:00 PM ET. A conference call will follow at 4:30 PM ET to discuss the results. The public can join by dialing (877) 407-0789 or (201) 689-8562. A replay of the call will be available from 7:30 PM ET on the same day until November 8, 2021. PetMed Express is recognized as America’s Most Trusted Pet Pharmacy, providing a range of pet health products through its hotline and website.
PetMed Express (NASDAQ: PETS) has appointed Matt Hulett as its new CEO and President, effective immediately. Hulett, a technology executive with over 30 years of experience, previously worked at Rosetta Stone and Expedia, focusing on digital consumer growth. Board Chairman Dr. Gian Fulgoni highlighted Hulett's expertise in technology and digital transformation, anticipating positive impacts on PetMeds' growth in the expanding digital pet pharmacy market. Hulett expressed excitement about the potential for PetMeds to capitalize on the $100 billion pet market, aiming for strong growth.
PetMed Express, Inc. (NASDAQ: PETS) announced the election of Jodi Watson and Peter Cobb as independent directors to its Board. Watson brings over 20 years of experience in digital transformation and leadership from companies like Petco and Williams-Sonoma. Cobb co-founded eBags.com and has expertise in digital retail and customer loyalty programs. Both will serve on the Audit, Compensation, and Corporate Governance Committees. The Board Chairman expressed confidence in their ability to contribute significantly as the company undergoes transformation.
PetMed Express (PETS) reported Q1 FY 2022 results with net sales of $79.3 million, down from $96.2 million a year ago. Net income was $4.4 million ($0.22/share), a decline from $7.8 million ($0.39/share) a year earlier. One-time charges totaled $717,000 due to the CEO's separation. Increased veterinary visits during the pandemic impacted sales, but future reorder sales are expected to be stronger. The company holds over $111 million in cash with no debt and declared a quarterly dividend of $0.30 per share, payable August 13, 2021.
PetMed Express (NASDAQ: PETS) will announce its financial results for the quarter ended June 30, 2021, on July 26, 2021, at 8:00 A.M. Eastern Time.
A conference call to discuss the results will follow at 8:30 A.M. ET, and is accessible to the public by dialing (888) 455-1758 or (203) 827-7025. A replay of the call will be available from July 26 at 10:00 A.M. until August 9, 2021.
Founded in 1996, PetMed Express delivers prescription and non-prescription medications for pets directly to consumers.
PetMed Express reported strong fiscal 2021 results, showing an 8.8% increase in net sales to $309.2 million and a 18.4% increase in net income to $30.6 million. Despite fourth-quarter challenges, with a 3.5% decrease in net sales to $71.7 million, the overall year reflected a successful pivot to e-commerce driven by COVID-19. The company acquired 443,000 new customers and improved average order size. An increased quarterly dividend of $0.30 per share was declared, reflecting ongoing confidence in future growth.
FAQ
What is the current stock price of PetMed Express (PETS)?
What is the market cap of PetMed Express (PETS)?
What does PetMed Express, Inc. do?
Where can I buy PetMeds products?
What recent partnerships has PetMeds announced?
What is the significance of PetMeds’ partnership with Hill's Pet Nutrition?
Does PetMeds offer pet insurance?
What other services does PetMeds provide?
Who are PetMeds' primary customers?
When is PetMeds' next conference call?
How can I contact PetMeds for investor relations?
What is PetCareRx?
